The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Is the era of chemotherapy over in CLL?
John Gribben and Stephan Stilgenbauer
• 4 Dec 2015
At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, John Gribben, MD, DSc, and Stephan Stilgenbauer, MD, summarise the current treatment landscape for CLL; they consider the place of chemotherapy as new treatment options are becoming increasingly available.
